Live Webinar

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|February 26, 2021

Supplements and Featured Publications

  • Implications of Oral Therapy in Metastatic Breast Cancer: Considerations for Delivery Networks

Implications of Oral Therapy in Metastatic Breast Cancer: Considerations for Delivery Networks

A recent stakeholder interchange convened by the Institute for Value-Based Medicine and The American Journal of Managed Care® brought together thought leaders in both the clinical and managed care communities to discuss oral therapeutics in the management of metastatic breast cancer (mBC). Participants discussed the shift of oncology treatments to oral agents, specifically in mBC; strategies for successful uptake of oral therapies, including the impact of coronavirus disease 2019 (COVID-19); and the incorporation of oral therapy for mBC into a value-based accountable payment model. This article is a summary of key points from the discussion with Bruce Feinberg, DO, vice president and chief medical officer at Cardinal Health Specialty Solutions in Atlanta, Georgia.

Download PDF

Related to this article

View more
Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Read more
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel. | Image: LinkedIn
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Read more